Stop by our booth #548

Our team of experts will be happy to talk about

your radiopharma production needs.

Don’t miss our daily presentations to learn:

- How to set up a (c)GMP radiopharmacy?

- How to manage a daily (c)GMP pet pdroduction?

More info

The introduction of PSMA labelled with 68Ga or 18F has revolutionized prostate cancer imaging. PSMA PET/CT outperforms in many instances standard imaging; it allows complete evaluation of the local tumor and lymph nodes, visceral and bone metastases with high accuracy in only one examination.

Two leading f igures of Nuclear Medicine: Prof. Stefano Fanti and Dr Horacio Amaral gave instructive presentations about applications on PSMA PET/CT in prostate cancer during IBA webinar.

Professor Stefano Fanti gave an overview of the clinical application with 68Ga-PSMA; the role of 68Ga-PSMA-11 in staging, in recurrence

setting, in therapy management and theranostic approach. Dr. Amaral shared his experience with both 68Ga-PSMA-11 and 18F-PSMA-1007.The presentation focused on the c o m p a r i s o n f ro m t h e c l i n i ca l perspective between the most used PSMA compound: 68Ga-PSMA and the most recent 18F version: 18F-PSMA -1007.

In addition to all questions answered at the end of this webinar, here are a few remaining ones, which Dr Fanti and Dr Amaral’s teams kindly answered:

• What about PSMA for treatment follow up? Is there any evidence that treatment does not modify PSMA?

• I would like to know you experience and opinion on hormonal therapy impact on PSMA uptake?

• Leaving aside PET better resolution versus SPECT, what do you think about 99mTc-PSMA?

• Since you have experience with both 68Ga and 18F-PSMA, have you experienced any difference in depicting small bone lesions with both targets? Would you say 68Ga-PSMA or 18F-PSMA do better or worse regarding bone lesions?

Read the answers

RADIOPHARMA SOLUTIONSNEWSLETTER N°20- SPRING 2018

Oliver Holderbaum Head of Global Sales RPS Oliver.Holderbaum@iba-group.com

Sylvain Savaria Vice President NA Sylvain.Savaria@iba-group.com

Li ChenSales Director ChinaChen.Li@iba-group.com

Claudia Ochoa Vice President Global Chemistry Solutions Claudia.Ochoa@iba-group.com

Peter Leitner Vice President APAC Peter.Leitner@iba-group.com

Ambrosio Moreno Vice President LATAM Ambrosio.Moreno@iba-group.com

Frederic Jodocy Vice President EMEAFrederic.jodocy@iba-group.com

IBA RadioPharma SolutionsChemin du cyclotron, 3 1348 Louvain-la-Neuve Belgium

Tél. : +32 10 201 275 Fax : + 32 10 47 59 00 info-cyclo@iba-group.com

THE CYCLONE® 18/9 WAS R I G G E D A T C H O N N A M N AT I O N A L U N I V E R S I T Y HOSPITAL (CNUH)

The Cyclone®18/9 was placed in its final position at Chonnam National University Hospital (CNUH) in South Korea. The installation is on track and the radiopharmacy will start its radiopharmaceuticals production this summer!

MEET IBA @SNMMI

iba-RadiopharmaSolutions.com

THE CYCLONE®18 INSTALLED IN KANAGAWA IS NOW READY FOR 18F PRODUCTION

THE CYCLONE® 18 INSTALLED AT XIAMEN UNIVERSITY HAS BEEN ACCEPTED

We are glad to announce that the Cyclone® 18 and the Synthera® synthesis modules have been accepted at Xiamen University in China. The new radiopharmacy is now ready for the production of FDG and FLT.

The Cyclone®18 was placed into its vault at Muni Seva Ashram (MSA) in India. The cyclotron will be installed by IBA team during this Summer. The cyclotron will be dedicated to the production of 18F for diagnosis of cancer. MSA set up two state of the art hospitals to provide medical care to the population. One provides general medical care and the other one focuses on oncology and nuclear medicine. Both hospitals charge

a token amount for care, which is fully subsidized by MSA if patients cannot afford it, thereby providing 100% free care to the most needy ones. IBA is really proud to be part of the project with the installation of a Cyclone®18. more info

SUCCESS STORIES

THE CYCLONE® KIUBE HAS BEEN SUCCESSFULLY RIGGED IN TAICHUNG

The Cyclone® KIUBE has been rigged at GMS Taichung production site in Taïwan for Unison Company Ltd. . The construction of the building is progressing and the installation of the cyclotron is ongoing.

WATCH THE WEBINAR: “PSMA PET-CT: A DISRUPTIVE TECHNOLOGY IN THE MANAGEMENT OF PROSTATE CANCER”

Left side: MIP of a negative [18F]PSMA-1007 scan showing normal biodistribution. Right side: Positive scan of a prostate cancer patient.

The Cyclone® 18 installed at JFE site, Suehiro-cho Tsurumi-ku Yokohama in Kanagawa (Japan) is now operational for radioisotope production. Aside from its routine FDG production, the radiopharmacy plans to become the principal source of 89Zr in Japan. The 89Zr should be commercially available in September 2018.

THE CYCLONE® 18 WAS RIGGED AT MUNI SEVA ASHRAM!

IBA RECEIVED THE ACCEPTANCE TEST OF THE CYCLONE®18 INSTALLED AT WUHAN

The site is equipped with a Cyclone®18 and a full Synthera® platform. The new radiopharmacy is now ready for the production of FDG.

A NEW POWERFUL COMPACT CYCLOTRON: THE CYCLONE®

KIUBE 300

Discover how the Cyclone® KIUBE was optimized to reach the highest production capacity with a PET cyclotron. The Cyclone® KIUBE can reach up to 300 μA, leading to greater capacity for shorter runs and to increased profitability. - Poster 2106

Oral Presentation: Sunday, June 24, 4:00 PM - Room 103C

THE FIRST CYCLONE®KIUBE’S SELF-SHIELDING HAS BEEN RIGGED AT LIEGE UNIVERSITY HOSPITAL. The Self-shielding has been placed into its vault at Liege University Hospital in Belgium. The Cyclone® KIUBE will dedicated to the production of 18F compounds for the detection of critical diseases.

ROUTINE PRODUCTION OF 18F-PSMA-1007 AND FIRST CLINICAL EXPERIENCE IN STAGING OF PROSTATE CANCER PATIENTS

Positron Pharma has already performed over 100 PET-scans using 18F-PSMA-1007. Don’t miss the opportunity to learn from their experience. - Poster 1490

Presentation: Monday, June 25, 3:00PM

INVESTIGATION OF 48V LABELED VO(ACAC)2 FOR CANCER IMAGING

The University of Chicago has successfully developed and optimized the cyclotron-based techniques for routine production of 48V, and efficient approaches to synthesize 48V-VO(acac)2 for conducting routine animal studies. - Poster 1102

Presentation: Sunday, June 24 6:30PM